BACKGROUND: Cholangiocarcinoma (CC) frequently presents at an advanced stage and the majority of patients are unresectable at diagnosis. We sought to examine our recent experience with surgical resection for hilar and peripheral CC. METHODS: A review of all CC patients who presented to our multidisciplinary liver cancer center for evaluation of their CC between January 2000 and August 2008 was performed. Demographics, therapeutic management, pathologic characteristics, and overall survival were analyzed. RESULTS: A total of 280 patients were evaluated over the 8-year period, and 222 patients (79%) were unresectable at presentation. Fifty-eight out of 280 patients were candidates for resection, of whom, 51 patients underwent resection. Hilar CC was identified in 27 patients (53%) and peripheral CC was present in 24 patients (47%). Morbidity and 90-day mortality were 61 and 9.8%, respectively. Overall, negative margin (R0) resection was achieved in 26 patients (51%). Using multivariate Cox regression analysis, only margin status was found to be a significant predictor of survival (p = 0.009). Compared with peripheral CC, hilar CC was associated with shorter overall survival (p = 0.001) and higher rates of positive margins (p = 0.001) and perineural invasion (p = 0.02), and no difference in angiolymphatic, portal vein, and lymph node involvement. CONCLUSIONS: Survival benefits can be achieved with resection for cholangiocarcinoma. Given the lack of effective alternative therapy, when confronted with the potential risk of positive margins or isolated nodal disease, we continue to advocate aggressive surgical resection for both hilar and peripheral CC with the ultimate goal of negative margin resection.
BACKGROUND:Cholangiocarcinoma (CC) frequently presents at an advanced stage and the majority of patients are unresectable at diagnosis. We sought to examine our recent experience with surgical resection for hilar and peripheral CC. METHODS: A review of all CC patients who presented to our multidisciplinary liver cancer center for evaluation of their CC between January 2000 and August 2008 was performed. Demographics, therapeutic management, pathologic characteristics, and overall survival were analyzed. RESULTS: A total of 280 patients were evaluated over the 8-year period, and 222 patients (79%) were unresectable at presentation. Fifty-eight out of 280 patients were candidates for resection, of whom, 51 patients underwent resection. Hilar CC was identified in 27 patients (53%) and peripheral CC was present in 24 patients (47%). Morbidity and 90-day mortality were 61 and 9.8%, respectively. Overall, negative margin (R0) resection was achieved in 26 patients (51%). Using multivariate Cox regression analysis, only margin status was found to be a significant predictor of survival (p = 0.009). Compared with peripheral CC, hilar CC was associated with shorter overall survival (p = 0.001) and higher rates of positive margins (p = 0.001) and perineural invasion (p = 0.02), and no difference in angiolymphatic, portal vein, and lymph node involvement. CONCLUSIONS: Survival benefits can be achieved with resection for cholangiocarcinoma. Given the lack of effective alternative therapy, when confronted with the potential risk of positive margins or isolated nodal disease, we continue to advocate aggressive surgical resection for both hilar and peripheral CC with the ultimate goal of negative margin resection.
Authors: W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart Journal: Ann Surg Date: 2001-10 Impact factor: 12.969
Authors: Fumito Ito; Rashmi Agni; Robert J Rettammel; Mark J Been; Clifford S Cho; David M Mahvi; Layton F Rikkers; Sharon M Weber Journal: Ann Surg Date: 2008-08 Impact factor: 12.969
Authors: P Neuhaus; S Jonas; W O Bechstein; R Lohmann; C Radke; N Kling; C Wex; H Lobeck; R Hintze Journal: Ann Surg Date: 1999-12 Impact factor: 12.969
Authors: T Todoroki; T Kawamoto; N Koike; H Takahashi; S Yoshida; H Kashiwagi; Y Takada; M Otsuka; K Fukao Journal: Br J Surg Date: 2000-03 Impact factor: 6.939
Authors: David J Rea; Manuel Munoz-Juarez; Michael B Farnell; John H Donohue; Florencia G Que; Brian Crownhart; Dirk Larson; David M Nagorney Journal: Arch Surg Date: 2004-05
Authors: Ka Wing Ma; Tan To Cheung; Wong Hoi She; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Wing Chiu Dai; Wan Hang Chiu; Chung Mau Lo Journal: World J Surg Date: 2018-03 Impact factor: 3.352
Authors: Kai Mao; Jieqiong Liu; Jian Sun; Jianlong Zhang; Jie Chen; Timothy M Pawlik; Lisa K Jacobs; Zhiyu Xiao; Jie Wang Journal: J Gastroenterol Hepatol Date: 2016-02 Impact factor: 4.029
Authors: John R Bergquist; Ryan T Groeschl; Tommy Ivanics; Christopher R Shubert; Elizabeth B Habermann; Michael L Kendrick; Michael B Farnell; David M Nagorney; Mark J Truty; Rory L Smoot Journal: HPB (Oxford) Date: 2016-08-18 Impact factor: 3.647